Cargando…

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Laihui, He, Yongzhu, Zhu, Guoqing, Xiao, Yongqiang, Song, Shengjiang, Ge, Xian, Wang, Tao, Xie, Jin, Deng, Wei, Hu, Zhigao, Shan, Renfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792109/
https://www.ncbi.nlm.nih.gov/pubmed/36578526
http://dx.doi.org/10.2147/JHC.S388965
_version_ 1784859562909630464
author Luo, Laihui
He, Yongzhu
Zhu, Guoqing
Xiao, Yongqiang
Song, Shengjiang
Ge, Xian
Wang, Tao
Xie, Jin
Deng, Wei
Hu, Zhigao
Shan, Renfeng
author_facet Luo, Laihui
He, Yongzhu
Zhu, Guoqing
Xiao, Yongqiang
Song, Shengjiang
Ge, Xian
Wang, Tao
Xie, Jin
Deng, Wei
Hu, Zhigao
Shan, Renfeng
author_sort Luo, Laihui
collection PubMed
description PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PATIENTS AND METHODS: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching. RESULTS: The median duration of conversion therapy was 108 (42–298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL, p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days, p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths. CONCLUSION: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy.
format Online
Article
Text
id pubmed-9792109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97921092022-12-27 Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? Luo, Laihui He, Yongzhu Zhu, Guoqing Xiao, Yongqiang Song, Shengjiang Ge, Xian Wang, Tao Xie, Jin Deng, Wei Hu, Zhigao Shan, Renfeng J Hepatocell Carcinoma Original Research PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PATIENTS AND METHODS: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching. RESULTS: The median duration of conversion therapy was 108 (42–298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL, p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days, p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths. CONCLUSION: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy. Dove 2022-12-22 /pmc/articles/PMC9792109/ /pubmed/36578526 http://dx.doi.org/10.2147/JHC.S388965 Text en © 2022 Luo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Luo, Laihui
He, Yongzhu
Zhu, Guoqing
Xiao, Yongqiang
Song, Shengjiang
Ge, Xian
Wang, Tao
Xie, Jin
Deng, Wei
Hu, Zhigao
Shan, Renfeng
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title_full Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title_fullStr Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title_full_unstemmed Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title_short Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
title_sort hepatectomy after conversion therapy for initially unresectable hcc: what is the difference?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792109/
https://www.ncbi.nlm.nih.gov/pubmed/36578526
http://dx.doi.org/10.2147/JHC.S388965
work_keys_str_mv AT luolaihui hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT heyongzhu hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT zhuguoqing hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT xiaoyongqiang hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT songshengjiang hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT gexian hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT wangtao hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT xiejin hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT dengwei hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT huzhigao hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference
AT shanrenfeng hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference